PRESS
Nov, 2018 - Press TG Therapeutics announces Phase I study of novel BTK inhibitor, TG-1701, in patients with relapsed or refractory B-cell malignancies, is open for Enrollment Read More Jan, 2018 - Press TG Therapeutics and Jiangsu Hengrui announce agreement for BTK inhibitor program for treatment of hematologic malignancies Read More |